CRISPR Therapeutics AG (CRSP) Interest Expenses (2015 - 2026)

CRISPR Therapeutics AG (CRSP) has 12 years of Interest Expenses data on file, last reported at $14.5 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses changed N/A year-over-year to $14.5 million; the trailing twelve-month figure through Mar 2026 stood at $14.5 million (up 606.03% YoY), and the FY2025 full-year result was $42.3 million, up 46.02% from the prior year.
• Interest Expenses rose to $14.5 million in Q1 2026, from $106000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $227.6 million in Q4 2023 to a low of $106000.0 in Q3 2025.
• A 5-year average of $25.5 million and a median of $10.6 million in 2023 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses soared 2962.5% in 2022 and plunged 96.74% in 2024, its largest moves.
• Tracing CRSP's Interest Expenses over 5 years: stood at $32.1 million in 2022, then soared by 608.4% to $227.6 million in 2023, then sank by 93.83% to $14.0 million in 2024, then slumped by 99.25% to $106000.0 in 2025, then soared by 13607.55% to $14.5 million in 2026.
• Business Quant data shows CRSP's Interest Expenses at $14.5 million in Q1 2026, $106000.0 in Q3 2025, and $475000.0 in Q2 2025.